Accessibility Statement Skip Navigation
  • Resources
  • Data Privacy
  • Contact Us
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • All Multimedia

        • All Multimedia
        • All Photos
        • All Videos
    • Business & Money
        • Auto & Transportation

        • Aerospace & Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads & Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking & Road Transportation
        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Accessories
        • Computer Hardware
        • Computer Networks
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High-Tech Security
        • Internet Technology
        • Nanotechnology
        • Semiconductors
        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art, Culture & Design
        • Books
        • Entertainment
        • Film & Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers & Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Projections or Forecasts
        • Financing Agreements
        • Insurance
        • Joint Ventures
        • Mutual Funds
        • Offerings
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Venture Capital
        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing/marketing agreements
        • New Products & Services
        • Obituary
        • Outsourcing Businesses
        • Overseas Real Estate (Non-US)
        • Personnel Announcements
        • Residential Real Estate
        • Small-Business Services
        • Socially Responsible Investing
        • Surveys, Polls & Research
        • Trade Show News
        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Accessories
        • Computer Electronics
        • Computer Hardware
        • Computer Networks
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Design Automation
        • Financial Technology
        • Mobile Devices/Apps
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Wireless Communications
        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Natural Gas Utilities
        • Oil & Energy
        • Oil & Gas Discoveries
        • Utilities
        • Water Utilities
        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation & Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking & Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Computer Accessories
        • Computer Networks
        • Mobile Devices/Apps
        • Telecommunications
        • Telecommunications Carriers & Services
        • Telecommunications Equipment
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wine & Spirits
        • Beverages
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food
        • Furniture & Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art, Culture & Design
        • Books
        • Entertainment
        • Film & Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infectious Disease Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • View All Health

        • Sports

        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports
        • Sports Equipment & Accessories
        • View All Sports

        • Travel

        • Amusement Parks & Tourist Attractions
        • Gambling & Casinos
        • Hotels & Resorts
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel
        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Animal Welfare
        • Corporate Social Responsibility
        • Economic News, Trends & Analysis
        • Education
        • Environmental Products & Services
        • European Government
        • Natural Disasters
        • Not-for-Profit
        • Public Safety
        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Children-related news
        • Disabled Persons
        • Diversity, Equity & Inclusion
        • Hispanic-oriented news
        • LGBTQ+
        • Religion
        • Senior Citizens
        • Veterans
        • Women-Related news
        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Request a Demo
    • Partnerships
    • Media Inquiries
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring Home
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us


    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • News Releases
      • Send a Release
      • Data Privacy
      • 2 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • News Releases
      • Send a Release
      • Data Privacy
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • News Releases
      • Send a Release
      • Data Privacy
      • General Inquiries
      • Request a Demo
      • Partnerships
      • Media Inquiries
      • Editorial Bureaus
      • News Releases
      • Send a Release
      • Data Privacy
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • All Multimedia
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Novel Immunogenicity Risk Assessment Platform, ISPRI, Facilitates Biologic Therapeutics Development

      EpiVax is an immunology company founded in 1998. We develop and employ extensive analytical capabilities in the field of computational immunology. We assess protein therapeutics for immunogenic risk and design more effective (and safer) vaccines. www.EpiVax.com .

      News provided by

      EpiVax, Inc.

      01 Apr, 2024, 20:00 CST

      Share this article

      Share this article


      PROVIDENCE, R.I., April 1, 2024 /PRNewswire/ -- In the pursuit of developing novel biologic entities, scientists harnessing the power of AI and generative biology depend on computational tools for predicting and managing immunogenicity risk – a critical characterization step in the candidate development process to ensure drug efficacy and safety in advance of clinical trials. Today marks a significant advancement in this endeavor with the publication of "In silico methods for immunogenicity risk assessment and human homology screening for therapeutic antibodies" in mAbs, which describes the ISPRI (Immunogenicity Screening and Protein Re-engineering Interface) toolkit, a web-based platform for in silico immunogenicity risk assessment of biologic therapeutics in preclinical development stages.

      Developed over many years by EpiVax bioinformaticians, ISPRI provides researchers with a secure interface comprised of integrated computational tools that enable a systematic approach to streamline the assessment and mitigation of immunogenic potential and accelerate overall preclinical development efforts.

      The tools, each of which play a critically important role in the assessment process, include: EpiMatrix for T cell epitope mapping, ClustiMer for the identification of epitope-dense regions that could be key to further testing/deimmunization, JanusMatrix for characterizing epitopes (the identification of potentially tolerated or actively tolerogenic epitopes, like Tregitopes), and OptiMatrix for sequence modifications to mitigate immunogenic risks.

      Notably, the ISPRI tools can be applied at different stages of development, from early-stage discovery for a high-throughput screening of hits, to comprehensive assessment of a lead candidate in preparation for IND-filing and development of an Integrated Summary of Immunogenicity (ISI).

      Further, the toolkit is useful for the screening of all biologic therapeutic modalities, from monoclonal antibodies to bi-specifics, multi-specifics, antibody-drug conjugates, enzyme replacement proteins, CAR-T, gene therapy products, and peptide drugs.

      Annie De Groot, MD, CSO, emphasized the significance of ISPRI in advancing biologic therapeutics development, stating that: "ISPRI stands as a pivotal tool in the pursuit of safer, more effective biologic therapeutics, empowering researchers to navigate the complexities of immunogenicity with precision and confidence."

      About EpiVax:

      EpiVax, a 26-year-old biotechnology company located in Providence, RI, is a leader in the field of immunogenicity assessment of biologics and vaccines. EpiVax partners with a global roster of companies, agencies, and academics to accelerate immunogenicity risk assessment by providing access to advanced computational immunology tools, like the ISPRI and iVAX toolkits, for investigations in a number of applications.

      Press Contact:

      Sarah Moniz, Associate Director of Business Development, EpiVax, Inc.
      [email protected]

      SOURCE EpiVax, Inc.

      Modal title

      Also from this source

      EpiVax Launches AI-Enhanced Models for Immunogenicity Prediction

      EpiVax Launches AI-Enhanced Models for Immunogenicity Prediction

      EpiVax, Inc. is pleased to announce the release of AI-enabled enhancements to ISPRI™, its proprietary in silico platform for assessing the...

      EpiVax Announces Laboratory Expansion and Streamlined, NAM-Centric In Vitro Services

      EpiVax Announces Laboratory Expansion and Streamlined, NAM-Centric In Vitro Services

      EpiVax, Inc., a recognized leader in immunogenicity risk assessment, announces the expansion of its laboratory facilities at its Providence, RI...

      More Releases From This Source

      Explore

      Health Care & Hospitals

      Health Care & Hospitals

      Medical Pharmaceuticals

      Medical Pharmaceuticals

      Biotechnology

      Biotechnology

      Clinical Trials & Medical Discoveries

      Clinical Trials & Medical Discoveries

      News Releases in Similar Topics

      Contact PR Newswire

      • General Inquiries
      • Request a Demo
      • Partnerships
      • Media Inquiries

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Become a Publishing Partner
      • Careers
      • Accessibility Statement
      • APAC – Simplified Chinese
      • APAC
      • APAC - Traditional Chinese
      • Arabic
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • United States
      • Vietnam

      My Services

      • All New Releases
      • Platform

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact Cision

      Products

      About

      My Services
      • All News Releases
      • Platform
      [email protected]
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookie Settings
      • Accessibility
      Copyright © 2026 Cision US Inc.